Simvastatin may improve myocardial perfusion abnormality in slow coronary flow

Cardiology

Volumn 110, Issue 1, 2008, Pages 39-44

  Cakmak, Mahmut ^a,c   Tanriverdi, Halil ^b   Cakmak, Nazmiye ^a   Evrengul, Harun ^b   Cetemen, Sebnem ^a   Kuru, Omur ^b  

^a DR SIYAMI ERSEK THORACIC AND CARDIOVASCULAR SURGERY TRAINING AND RESEARCH HOSPITAL   (Turkey)

^b PAMUKKALE UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

^c Acibadem Bursa Hospital   (Turkey)

Author keywords

Atherosclerosis; Endothelial function; Myocardial ischemia; Slow coronary flow; Statin; TIMI frame count

Indexed keywords

METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; NITRATE; SIMVASTATIN;

ADULT; ANGINA PECTORIS; ARTICLE; BLOOD CLOT LYSIS; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; CORRELATION ANALYSIS; FEMALE; FOLLOW UP; HEART INFARCTION; HEART MUSCLE PERFUSION; HUMAN; MAJOR CLINICAL STUDY; MALE; MYOCARDIAL DISEASE; PRIORITY JOURNAL; SINGLE DRUG DOSE; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

ADULT; ANGINA PECTORIS; BLOOD CHEMICAL ANALYSIS; BLOOD FLOW VELOCITY; CHEST PAIN; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CORONARY ANGIOGRAPHY; CORONARY CIRCULATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; PROBABILITY; PROSPECTIVE STUDIES; RISK ASSESSMENT; SIMVASTATIN; STATISTICS, NONPARAMETRIC; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TREATMENT OUTCOME;

EID: 41749123670     PISSN: 00086312     EISSN: None     Source Type: Journal    
DOI: 10.1159/000109405     Document Type: Article

References (30)

1. Tambe AA, Demany MA, Zimmerman HA, Masearanhas E: Angina pectoris and slow flow velocity of dye in coronary arteries, a new angiographic finding. Am Heart J 1972;84:66-71.
2. Mosseri M, Yarom R, Gotsman MS, Hasin Y: Histologic evidence for small-vessel coronary artery disease in patients with angina and patent large coronary arteries. Circulation 1986;74:964-972.
3. Mangieri E, Macchiarelli G, Ciavolella M, Barilla F, Avella A, Martinotti A, et al: Slow coronary flow: clinical and histopathological features in patients with otherwise normal epicardial coronary arteries. Cathet Cardiovasc Diagn 1996;37:375-381.
4. Ciavolella M, Avella A, Bellagamba S, Mangieri E, Nigri A, Reale A: Angina and normal epicardial coronary arteries radionuclide features and pathophysiological implications at long term follow up. Coron Artery Dis 1994;5:493-499.
5. Cesar LAM, Ramires JAF, Serrano CV Jr, Meneghetti JC, Antonelli RH, da-Luz PL, et al: Slow coronary run-off in patients with angina pectoris: clinical significance and thallium-201 scintigraphic study. Braz J Med Biol Res 1996;29:605-613.
6. Gibson CM, Cannon CP, Daley WL, Dodge JT Jr, Alexander B Jr, Marble SJ, et al: TIMI frame count: a quantitative method of assessing coronary artery flow. Circulation 1996;93:879- 888.
7. Kaul S, Finkelstein DM, Homma S, Leavitt M, Okada RD, Boucher CA: Superiority of quantitative exercise thallium-201 variables in determining long-term prognosis in ambulatory patients with chest pain: a comparison with cardiac catheteterization. J Am Coll Cardiol 1998;12:25-34.
8. Kemp HG, Elliott W, Gorlin RD: The anginal syndrome with normal coronary arteriography. Trans Assoc Am Physicians 1967;80:59.
9. Kurtoglu N, Akcay A, Dindar I: Usefulness of oral dipyridamole therapy for angiographic slow coronary artery flow. Am J Cardiol 2001;87:777-779.
10. Camsari A, Pekdemir H, Cicek D, Polat G, Akkus MN, Doven O, et al: Endothelin-1 and nitric oxide concentrations and their response to exercise in patients with slow coronary flow. Circ J 2003;67:1022-1028.
11. Sezgin AT, Sigirci A, Barutcu I, Topal E, Sezgin N, Ozdemir R, et al: Vascular endothelial function in patients with slow coronary flow. Coron Artery Dis 2003;14:155-161.
12. Pekdemir H, Cin VG, Cicek D, Camsari A, Akkus N, Doven O, et al: Slow coronary flow may be a sign of diffuse atherosclerosis. Contribution of FFR and IVUS. Acta Cardiol 2004;59:127-133.
13. Chilian WM, Layne SM, Klausher EC, Eastham CL, Marcus ML: Redistribution of coronary microvascular resistance produced by dipyridamole. Am J Physiol 1989;256:383-390.
14. Zeiher AM, Schachinger V, Hohnloser SH, Saurbier B, Just H: Coronary atherosclerotic wall thickening and vascular reactivity in humans: elevated high-density lipoprotein levels ameliorate abnormal vasoconstriction in early atherosclerosis. Circulation 1994;89:2525-2532.
15. Tanriverdi H, Evrengul H, Enli Y, Kuru O, Seleci D, Tanriverdi S, et al: Effect of homocysteine induced oxidative stress on endothelial function in coronary slow flow. Cardiology 2007;107:313-320.
16. Tanriverdi H, Evrengul H, Tanriverdi S, Kuru O, Seleci D, Enli Y, et al: Carotid intima media thickness in coronary slow flow; relationship with plasma homocysteine levels. Coron Artery Dis 2006;17:331-337.
17. Demirkol MO, Yaymac? B, Mutlu B: Dipyridamole myocardial perfusion single photon emission computed tomography in patients with slow coronary flow. Coron Artery Dis 2002;13:223-229.
18. Turhan H, Saydam GS, Erbay AR, Ayaz S, Yasar AS, Aksoy Y, et al: Increased plasma soluble adhesion molecules: ICAM-1, VCAM-1, and E-selectin levels in patients with slow coronary flow. Int J Cardiol 2005;98:450-456.
19. Nair P, Roguin A: Statins and the acute coronary syndrome: 'the early bird catches the worm'. Int J Clin Pract 2006;60:716-727.
20. Wassmann S, Faul A, Hennen B, Scheller B, Bohm M, Nickenig G: Rapid effect of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibition on coronary endothelial function. Circ Res 2003;93:98-103.
21. Stroes ES, Koomans HA, de Bruin TW, Rabelink TJ: Vascular function in the forearm of hypercholesterolemic patients off and on lipid-lowering medication. Lancet 1995;346:467-471.
22. Wassmann S, Laufs U, Muller K, Konkol C, Ahlbory K, Baumer AT, et al: Cellular antioxidant effects of atorvastatin in vitro and in vivo. Arterioscler Thromb Vasc Biol 2002;22:300-305.
23. Girona J, La Ville AE, Sola R, Plana N, Masana L: Simvastatin decreases aldehyde production derived from lipoprotein oxidation. Am J Cardiol 1999;83:846-851.
24. Nazzaro P, Manzari M, Merlo M, Triggiani R, Scarano A, Ciancio L, et al: Distinct and combined vascular effects of ACE blockade and HMG-CoA reductase inhibition in hypertensive subjects. Hypertension 1999;33:719-725.
25. Hernandez-Perera O, Perez-Sala D, Navarro-Antolin J, Sanchez-Pascuala R, Hernandez G, Diaz C, Lamas S: Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells. J Clin Invest 1998;101:2711-2719.
26. Sarkar K, Sinha AK, Mehta JL: The role of statins in endothelial dysfunction in hypertension. Curr Opin Cardiol 206;21:316-321.
27. Dupuis J, Tardif JC, Cernacek P, Theroux P: Cholesterol reduction rapidly improves endothelial function after acute coronary syndromes. The RECIFE (reduction of cholesterol in ischemia and function of the endothelium) trial. Circulation 1999;99:3227-3233.
28. Plenge JK, Hernandez TL, Weil KM, Poirier P, Grunwald GK, Marcovina SM, et al: Simvastatin lowers C-reactive protein within 14 days: an effect independent of low-density lipoprotein cholesterol reduction. Circulation 2002;106:1447-1452.
29. Jialal I, Stein D, Balis D, Grundy SM, Adams-Huet B, Devaraj S: Effect of hydroxymethyl glutaryl coenzyme A reductase inhibitor therapy on high sensitive C-reactive protein. Circulation 2001;103:1933-1935.
30. Weber C, Erl W, Weber KS, Weber PC: HMG-CoA reductase inhibitors decrease CD11b expression and CD11b-dependent adhesion of monocytes to endothelium and reduce increased adhesiveness of monocytes isolated from patients with hypercholesterolemia. J Am Coll Cardiol 1997;30:1212-1217.